Neurocrine review highlights key differences between tardive dyskinesia drugs

SPARC announces consolidation of R&D laboratories and facilities

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million

Shilpa Medicare announces positive Phase 3 results for Oeris

OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days

Granules Life Sciences receives first FDA approval for Hyderabad facility

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025

Zydus Lifesciences secures FDA tentative approval for Olaparib tablets

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers

Alembic announces USFDA final approval for Dasatinib Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets

Cipla to acquire Inzpera Healthsciences for Rs. 110.65 Cr

The transaction is expected to be completed within one month from the signing of the definitive agreements.